SLU-PP-332: the “exercise mimetic” that lives entirely in mice

SLU-PP-332 is the compound behind a run of “exercise in a pill” headlines. The science underneath the hype is genuinely interesting: it is a synthetic small molecule that switches on a family of nuclear receptors tied to how muscle burns fuel. But there is one fact that has to sit above everything else, so we will say it first and repeat it: every result you are about to read comes from mice and cell cultures. There are no human studies of SLU-PP-332 at all.

What it actually is

SLU-PP-332 is a synthetic agonist of the estrogen-related receptors (ERRs) — a family of orphan nuclear receptors with three members, ERRα, ERRβ and ERRγ. It activates all three but is most potent at ERRα, which is why it is described as a pan-ERR agonist.^[1] The “SLU” in the name is Saint Louis University, where the discovery work was done; it is a laboratory chemical tool, not a branded medicine.

The ERRs matter because they sit high in the control network for oxidative metabolism. Genetic evidence long implicated them in skeletal-muscle exercise capacity, but designing a compound that could actually turn ERRα on in vivo had proven difficult. SLU-PP-332 was reported as a molecule potent enough, and with good enough pharmacokinetics, to be used as a chemical probe in living animals.^[1]

The mechanism: mimicking the endurance-training program

Aerobic exercise reshapes muscle by driving mitochondrial biogenesis and shifting fibers toward a fatigue-resistant, oxidative type. The idea behind an ERR agonist is to trigger that same transcriptional program pharmacologically. In a skeletal-muscle cell line, SLU-PP-332 increased mitochondrial function and cellular respiration.^[1] When given to mice, it increased the proportion of type IIa oxidative muscle fibers and switched on an ERRα-dependent “acute aerobic exercise” gene program — and that ERRα activation was necessary for the effect on endurance.^[1]

This is the same logic explored by other so-called exercise-mimetic and mitochondrial compounds we cover, such as MOTS-c, the mitochondrial-derived peptide, and the NAD⁺-adjacent enzyme target behind 5-amino-1MQ. In each case the promise is the biochemistry of training without the training — and in each case the honest reader has to ask how far the animal data actually reach.

What happened in the animals

The headline behavioral result is endurance. Mice treated with SLU-PP-332 ran longer, and the effect depended on ERRα.^[1] A follow-up study looked at metabolism directly: in diet-induced obese mice and in ob/ob mice, SLU-PP-332 reproduced several exercise-like benefits, including increased energy expenditure and fatty-acid oxidation, with those changes accompanied by decreased fat-mass accumulation.^[2] In the metabolic-syndrome models it reduced obesity and improved insulin sensitivity.^[2] Pan-ERR agonism in this chemical series has also been studied in the heart, where related compounds enhanced cardiac fatty-acid metabolism and mitochondrial function in rodent heart failure models.^[3]

Taken together, these are a coherent and legitimately exciting set of rodent findings: a single molecule that appears to nudge whole-body metabolism in the direction that endurance exercise does. That is exactly why it drew attention. It is also exactly the point at which caution has to take over.

The honesty point: this is preclinical, full stop

Here is the part the headlines tend to skip. There are no clinical trials of SLU-PP-332. The evidence base is entirely mouse and in-vitro. That means there is no human data on whether it works, no human data on how much would be safe, no human dosing, and no long-term safety profile of any kind. Chronic, systemic activation of a master metabolic regulator across many tissues is precisely the sort of intervention whose risks only become visible in careful human studies — and those studies do not exist.

This is worth stressing because “exercise mimetic” is a phrase that invites people to treat a lab tool as a product. The gap between a rodent proof-of-concept and something a person should ingest is enormous. The same discipline applies to any longevity-adjacent compound: even an agent with a real randomized human trial, like the rapamycin work we cover in the PEARL trial, has to be read carefully for what it did and did not show. SLU-PP-332 is several steps behind that — it has no human trial at all.

“For sale” does not mean “for use”

SLU-PP-332 is not a drug, not a dietary supplement and not approved by any regulator. Despite this, it is sold online, marketed to the research-chemical and biohacking crowd. Anything sold under that name is an unregulated compound with no verified purity, no quality control and — to repeat the load-bearing fact — no human safety data whatsoever. We do not provide dosing for it, because there is no legitimate human dose to provide.

The honest bottom line

SLU-PP-332 is a fascinating research compound. It is one of the cleaner demonstrations that a nuclear-receptor agonist can switch on an endurance-exercise-like program and shift metabolism in mice. If pharmacological exercise mimetics ever become real medicines, work like this is part of the origin story. But origin story is the operative phrase. As of now it lives entirely in rodents and cell culture, with zero human evidence for either benefit or safety. The appropriate response is scientific curiosity — not a purchase.